Signed in as:
filler@godaddy.com
A differentiated platform
NM320 is built on a modified tetracycline scaffold designed to enhance stability, lipophilicity, and retinal exposure while supporting new intellectual property.
Engineered modifications are intended to:
• Enhance retinal stability
• Improve tissue penetration
• Preserve bioenergetic regulation
• Support sustained retinal cell protection
Designed for direct retinal access
NM320 is formulated as a proprietary lipophilic microemulsion designed to penetrate ocular barriers and deliver localized exposure behind the eye.
Key design features include:
• High lipophilicity to support ocular penetration
• Proprietary microemulsion delivery
• Demonstrated tissue accumulation
• Minimal systemic exposure
• Potential for infrequent dosing
Preclinical studies supporting advancement
In established preclinical AMD models, topical NM320 demonstrated protective activity, including preservation of retinal pigment epithelial cells.
These findings support continued advancement toward early clinical development and further evaluation of NM320 as a non-invasive retinal therapy.
NM320 Prevents retinal degeneration
